The Nonoperative Management of Rectal Cancer
J. Joshua Smith, MD, PhD, FACS, Memorial Sloan Kettering Cancer Center, highlights the nonoperative management of rectal cancer.
Transcript
I'm Josh Smith, a surgical oncologist/colorectal surgeon at Memorial Sloan Kettering—an associate member there.
Today I'll be discussing inoperative management for rectal cancer. Time to continue waiting or is watch and wait really ready for prime time?
Watch and wait is a hot topic today in colorectal cancer because of the increasing demand for patients for organ preservation, the increasing number of trials that have come out as it relates to total neoadjuvant therapy, showing increased response rates.
Then, the recent data that's been presented at ASCO, and now recently accepted for publication of the OPRA trial, which I'll present today, suggesting that more than half of the patients treated with consolidation type total neoadjuvant therapy can preserve the rectum, which is really a paradigm changing approach for patients with rectal cancer.
Disclaimer: The views and opinions expressed are those of the author(s) and do not necessarily reflect the official policy or position of Oncology Learning Network or HMP Global, their employees, and affiliates. Any content provided by our bloggers or authors are of their opinion and are not intended to malign any religion, ethnic group, club, association, organization, company, individual, anyone, or anything.
